Table 1.

Clinical laboratory characteristics of patient A.1

	A.1	Reference range*
CD4:CD8 ratio	1.46–3.54	0.74–5.17
CD4+ T cells	427–795/μL 37.3–58.9%	358–1565/μL 27.0–62.2%
CD8+ T cells	132–342/μL ↓ 16.5–25.5% ↓	149–911/μL 11.2–50.8%
CD8+ central memory (CD62L+ CD45RA−)	14–38/μL ↓ 1.5–5.5%	25–180/μL 1.5–10.3%
CD8+ effector memory (CD62L− CD45RA−)	4–9/μL ↓ 0.4–1.3% ↓	24–175/μL 1.1–9.2%
CD8+ Temra (CD62− CD45RA+)	4–6/μL ↓ 0.6–0.6% ↓	11–172/μL 0.7–7.8%
CD4+ CD25+ T cells	114–224/μL ↓ 11.3–18.9% ↓	139–1223/μL 10.6–41.2%
DNαβT cells (CD4− CD8− TCRα/β+)	14–32/μL ↑ 1.3–3.0% ↑	2–23/μL 0.1–1.3%
γδT cells (TCRγ/δ+)	22–145/μL 2.2–11.5% ↑	5–261/μL 0.3–10.4%
CD4 + HLA-DR + T cells	20–115/μL ↑ 1.5–11.4% ↑	0–139/μL 0.0–6.8%
NK cells (CD56+ CD16+)	30–131/μL ↓ 2.9–12.9% ↓	87–729/μL 4.6–34.6%
Memory B cells** (CD20+ CD27+)	0–17/μL ↓ 0.0–1.5% ↓	12–118/μL 0.7–6.3%
IgG, serum***	294–413 ↓	549–1584 mg/dL
IgA, serum	15–33 ↓	45–359 mg/dL
IgM, serum	26–88 ↓	23–259 mg/dL
Neutrophils	1.18–6.96 K/μL ↓↑ 49.6–81.5% ↑	1.56–7.87 K/μL 29.8–77.0%
Eosinophils	0.043–0.570 K/μL ↑ 0.6–9.2% ↓↑	0.03–0.47 K/μL 0.0–7.0%
Monocytes	0.15–0.40 K/μL ↓ 3.5–10.5% ↓	0.19–0.86 K/μL 4.2–12.5%

A minimum of three tests from independent blood draws are included for each row. Percentages indicate % of lymphocytes for lymphocyte populations and % of leukocytes for non-lymphocyte populations.

*Listed ranges reflect the aggregate of ranges used by the NIH Clinical Center for each age (as established at the time of testing) at which blood draws from patient A.1 are included. In some instances, lab values fall outside the corresponding age-matched reference range but do not fall outside the aggregate range.

**Prior to receiving rituximab.

***Prior to receiving IVIG